Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
0.2200
+0.0200 (10.00%)
At close: Jan 2, 2026, 4:00 PM EST
0.1931
-0.0269 (-12.23%)
After-hours: Jan 2, 2026, 8:00 PM EST
Can-Fite BioPharma Revenue
Can-Fite BioPharma had revenue of $101.00K in the half year ending June 30, 2025, a decrease of -36.08%. This brings the company's revenue in the last twelve months to $560.00K, down -16.04% year-over-year. In the year 2024, Can-Fite BioPharma had annual revenue of $674.00K, down -9.29%.
Revenue (ttm)
$560.00K
Revenue Growth
-16.04%
P/S Ratio
44.03
Revenue / Employee
$112,000
Employees
5
Market Cap
24.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 674.00K | -69.00K | -9.29% |
| Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
| Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
| Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
| Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
| Dec 31, 2019 | 2.03M | -1.79M | -46.81% |
| Dec 31, 2018 | 3.82M | 3.03M | 384.16% |
| Dec 31, 2017 | 789.00K | 624.00K | 378.18% |
| Dec 31, 2016 | 165.00K | 3.00K | 1.85% |
| Dec 31, 2015 | 162.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 467.66K | -278.63K | -37.34% |
| Dec 31, 2010 | 746.29K | -125.25K | -14.37% |
| Dec 31, 2009 | 871.53K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CANF News
- 10 days ago - Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change - GlobeNewsWire
- 17 days ago - Can-Fite Provides Update on Clinical and Financial Status - GlobeNewsWire
- 6 weeks ago - Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil - GlobeNewsWire
- 4 months ago - Can-Fite Reports H1 2025 Financial Results and Clinical Update - GlobeNewsWire
- 5 months ago - Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone - GlobeNewsWire
- 5 months ago - Can-Fite Announces Up To $15.0 Million Public Offering - GlobeNewsWire
- 5 months ago - Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia - GlobeNewsWire
- 9 months ago - Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients - GlobeNewsWire